Madrid, Spain – August 29, 2025 – Breakthroughs in cardiovascular medicine presented at the European Society of Cardiology Congress 2025 offer potential new avenues for treating high blood pressure and high cholesterol, conditions affecting millions globally. New data reveals a novel medication directly reducing aldosterone levels shows promise, alongside a twice-yearly cholesterol-lowering injection demonstrating faster results and fewer side effects than customary statins.
These advancements arrive at a critical juncture, as cardiovascular disease remains a leading cause of death worldwide. High blood pressure and cholesterol contribute considerably too heart failure, stroke, and other life-threatening conditions. The findings unveiled today could reshape treatment protocols, offering improved outcomes and quality of life for patients struggling with these prevalent health challenges. Further research and eventual widespread adoption hinge on continued clinical trials and regulatory approvals.
A new medication, Baxdrostat, represents a different approach to managing high blood pressure. Unlike existing treatments that block the effects of aldosterone, Baxdrostat directly lowers its levels in the body.This distinction, according to prof Paul Leeson, a cardiologist and professor of cardiovascular medicine at the University of Oxford who was not involved in the trial, could prove significant. “For many years, we have had medications that are able to block aldosterone working but they do not actually lower levels of aldosterone, so patients may still experience adverse effects of the substance,” Leeson explained. “Baxdrostat … is one version of a new range of medications that work differently, and directly reduce the levels of aldosterone.”
The clinical trial supporting Baxdrostat’s development was conducted across multiple countries and included a diverse patient population, encompassing both men and women from various ethnic backgrounds. This broad representation, Leeson emphasized, “helps ensure the findings are relevant to the range of patients we see with blood pressure problems.”
In a separate presentation, doctors in Madrid highlighted promising results from trials of Leqvio (inclisiran), a cholesterol-lowering jab manufactured by Novartis. The data indicated that patients receiving Leqvio twice a year achieved their cholesterol targets more rapidly compared to those on other therapies. Crucially, participants also reported experiencing less muscle pain, a frequent and frequently enough debilitating side effect associated with statin medications.
